摘要
目的:观察和比较B细胞性非霍奇金淋巴瘤患者应用氟达拉滨后外周血淋巴细胞表型的变化特点及规律。方法:应用流式细胞术测定应用氟达拉滨为基础的化疗方案(n=5)、CHOP方案(n=9)及利妥昔单抗加CHOP(R加CHOP)方案(n=7)化疗后的B细胞性非霍奇金淋巴瘤患者及健康志愿者(n=51)的外周血淋巴细胞表型。结果:应用氟达拉滨化疗患者的淋巴细胞、NK细胞、T淋巴细胞及CD4+T淋巴细胞计数均显著低于应用CHOP方案及应用R加CHOP方案患者。应用氟达拉滨组患者与R加CHOP组患者B淋巴细胞计数未存在显著差异,但2组均显著低于应用CHOP方案组患者B淋巴细胞计数结果。结论:氟达拉滨可引起患者机体显著的免疫抑制。在应用氟达拉滨为基础的化疗过程中有必要对外周血淋巴细胞亚群进行监测。
Objective： To observe the characteristics of lymphocyte phenotype in fludarabine treated B-cell non- Hodgkin＇s lymphoma（NHL） patients. Method： Lymphocyte phenotype in peripheral blood from 5 fludarabine treated, 9 CHOP treated, 7 Rituximab＋CHOP（R＋CHOP） treated B-NHL patients and 51 healthy subjects were detected using flow cytometry. Result：The decreases in lymphocyte, NK cell, CD3^＋ T and CD4^＋T cell counts were more profound than those in CHOP and R＋CHOP treated patients. No significance of B cell count was found between in fludarabine and R＋CHOP treated patients, but both results were marked lower than that in CHOP treated patients. Conclusion： Fludarabine may cause significant immunosuppression. It＇s necessary to monitor peripheral lymphocyte phenotype during fludarabine-based chemotherapy.
出处
《临床血液学杂志》
CAS
2007年第5期259-261,共3页
Journal of Clinical Hematology
关键词
淋巴瘤
非霍奇金
氟达拉滨
淋巴细胞表型
Non-Hodgkin＇s lymphoma
Fludarabine phosphate
Lymphocyte phenotype
